News Release:

Jun. 23,  2010

NIH Awards Grant to Joint ICGEB-Emory Vaccine Center in New Delhi, India

News Article ImageThe grant was awarded to the two institutions through the Indo-US Vaccine Action Program of the National Institute of Allergy and Infectious Diseases.

The Emory Vaccine Center (EVC) and the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India, have been awarded a grant from the National Institutes of Health to develop vaccines against HIV subtype C. Subtype C is the predominant HIV virus strain circulating in India and is responsible for more than 50 percent of HIV infections worldwide.

The grant was awarded to the two institutions through the Indo-US Vaccine Action Program of the National Institute of Allergy and Infectious Diseases.

In 2008 the two institutions established a joint ICGEB-EVC vaccine center in New Delhi. This collaborative initiative in India is supported in part by the Emory Global Health Institute, whose mission is to advance Emory University's efforts to improve health around the world. The other contributors to this initiative are the Emory University School of Medicine, the Emory Vaccine Center, the Emory Departments of Medicine and Pediatrics, and the Emory Center for AIDS Research (CFAR).

The collaborative research programs between faculty members at the joint center focus on the basic understanding of the pathogenesis and immunology of infections, leading to the development of effective vaccines against infectious diseases of global importance, for example, tuberculosis, HIV, hepatitis C virus, and dengue.

Leaders of the grant program are Dr. Shahid Jameel, Group Leader, Virology Group, ICGEB, New Delhi, and Dr. Rama Amara, Associate Professor, EVC,

The goal of the Indo-U.S Vaccine Action Program, established in 1987, is to support collaborative vaccine-related research projects that ultimately reduce the burden of infectious diseases of importance in India, the United States, the South Asian region and globally. Under this agreement, Dr. Jameel will receive Rs. 8.73 million (equivalent of $194,000) from the Department of Biotechnology, Government of India, and Dr. Amara will receive $499,456 from the National Institutes of Health (NIH) for their project titled "Design and testing of a CD40 ligand-adjuvanted HIV virus- like particle (VLP) as a candidate vaccine against HIV/AIDS."

The International Centre for Genetic Engineering and Biotechnology (ICGEB) is an international organization established as a center of excellence for research and training in molecular biology and biotechnology and dedicated to advanced research and training with special regard to the needs of the developing world.

The Emory Vaccine Center (EVC) includes a renowned group of immunologists, virologists and microbiologists and one of the largest worldwide concentrations of investigators in an academic medical center working on vaccine development. 

###

News Release Tools